PrecivityAD2 is a blood test for amyloid pathology used only with a clinician's evaluation for Alzheimer's or other cognitive decline. Adults with new memory symptoms can use it correctly by starting with an experienced clinician rather than seeking the test alone for answers.
The test measures two plasma ratios and produces an Amyloid Probability Score 2 from 0 to 100. According to C2N Diagnostics, the score estimates the likelihood of amyloid pathology the FDA clearance announcement. A single draw is less invasive than a brain PET scan or spinal-fluid test.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is the test for?
- How does the score fit into a visit?
- Why does a positive result not equal dementia?
- What should you do about new symptoms?
Who is the test for?
According to C2N Diagnostics, the clearance covers adults age 40 and older with signs or symptoms of cognitive impairment who are already being evaluated. As the Alzheimer's Association explains, the test is indicated only as an adjunct to assessment by health professionals experienced in cognitive-impairment evaluation the Association's clearance summary. It is not for screening people without symptoms or for diagnosis by itself.
Seeing age 40 in a headline can suggest routine testing starts at 40. It does not. As summarized by Medical News Today, newly symptomatic adults should pursue clinician-led evaluation rather than seek the test alone for reassurance the practical guidance summary.
How does the score fit into a visit?
AJMC reporting describes an evaluation that includes history, neurologic exam, and cognitive testing, with imaging or spinal-fluid testing sometimes still needed. The blood score adds amyloid information to that assessment rather than replacing it.
A single blood draw is less invasive than PET or lumbar puncture and can speed next decisions about care. AJMC reported research in 1,310 patients with mild impairment or dementia seen by 165 physicians. In that study, primary-care diagnostic accuracy rose from 65% before to 93% after receiving PrecivityAD2 results the accuracy report.
Why does a positive result not equal dementia?
Amyloid buildup signals pathology linked to Alzheimer's. As AJMC reporting stresses, a positive amyloid result does not by itself equal clinical Alzheimer's dementia. A clinician must weigh the result with history, exam findings, and cognitive testing.
That context decides whether amyloid explains the symptoms and what should happen next. A low score points toward lower likelihood and a high score toward higher likelihood. Neither score alone settles the diagnosis without clinical judgment.
What should you do about new symptoms?
Start with primary care or a memory clinic rather than shopping for a blood test. Bring specific examples and a complete record.
Ask whether an Alzheimer's-focused evaluation is appropriate and what a blood result would change. Leave with a written plan for follow-up, referrals, and when to return if symptoms worsen. Bring that plan to the next visit and share it with family or caregivers who observe daily function.
- Note when symptoms started, what tasks changed, and what a close observer sees.
- Bring medicines, medical history, and prior test results.
- Ask what clinical assessment, cognitive testing, or follow-up the clinician advises.
- Discuss how an amyloid result would or would not change next steps.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
- Vitamin Supplements in the 2026 WHO Dementia Guideline: Questions Adults Over 65 Can Discuss With a Clinician
- Healthy Diets in the 2026 WHO Dementia Guideline: Questions Adults Over 65 Can Discuss With a Clinician
